Episode 7: Three Benefits of GLP-1s that Aren't Weight Loss

Welcome back to Peptides for Women podcast!In today's episode, we’re talking about three major benefits you can get from using a GLP-1s beyond weight loss. You’ll see that GLP-1s can help regulate your blood sugar, calm inflammation, and support your liver so you feel better day-to-day.BENEFIT #1: Better Glucose & Insulin RegulationHow GLP-1s slow gastric emptying, which means steadier blood sugar after mealsThe impact on insulin sensitivity and long-term metabolic healthBENEFIT #2: Lower InflammationMy personal story: how tirzepatide helped relieve my hip pain and plantar fasciitisWhat the research is showing about inflammation markers improving on GLP-1 therapyBENEFIT #3: Improved Liver HealthHow GLP-1s can lower liver enzymes like ALT, AST, and GGTThe link between fatty liver, perimenopause, and insulin resistanceWhat early research says about GLP-1s as a potential therapy for NAFLD (non-alcoholic fatty liver disease)🔗 Resources:1.⁠ Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial —  https://pubmed.ncbi.nlm.nih.gov/28526920/2. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program — https://pubmed.ncbi.nlm.nih.gov/35724304/3. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes — https://pubmed.ncbi.nlm.nih.gov/37874653/4. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials — https://pubmed.ncbi.nlm.nih.gov/36056351/5. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials — https://pubmed.ncbi.nlm.nih.gov/36467859/6. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway — https://pubmed.ncbi.nlm.nih.gov/33641439/7. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis — https://pubmed.ncbi.nlm.nih.gov/33185364/8. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study — https://pubmed.ncbi.nlm.nih.gov/26608256/9. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis — https://pubmed.ncbi.nlm.nih.gov/38856224/Links & Resources:🔗 Learn more at: ⁠⁠⁠⁠⁠⁠⁠⁠elliemd.com/JenniferWoodwardNutrition⁠⁠⁠⁠⁠⁠⁠⁠🎯 Take my free peptide quiz and get a personalized, midlife-smart roadmap for the peptides that actually match your symptoms and goals: ⁠https://quiz.jenniferwoodwardnutrition.com/peptide-quiz🎓 Enroll in the Peptides for Practitioners Certification Course and get $100 off for podcast subscribers: ⁠⁠⁠⁠⁠https://www.carrotsncake.com/offers/TrVo7mCz?coupon_code=PFPJENNIFER⁠⁠⁠⁠⁠🧬 Want to pair GLP-1s with functional lab testing? ⁠⁠⁠⁠⁠https://learn.jenniferwoodwardnutrition.com/invitation⁠⁠⁠⁠⁠📩 Grab The Body Edit Guide here for full protocols, labs, and more: ⁠⁠⁠⁠⁠https://stan.store/jenniferwoodwardnutrition/p/get-the-body-edit⁠⁠⁠⁠⁠‼️Disclaimer‼️This podcast is for informational purposes only and does not provide medical advice. Always speak with your licensed healthcare provider before starting or changing any medication or treatment plan.